Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -94.53% | -33.37% | |||
| Gross Profit | 115.33% | 33.30% | |||
| SG&A Expenses | -33.11% | 57.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -74.90% | -18.33% | |||
| Operating Income | 89.05% | 18.25% | |||
| Income Before Tax | 89.62% | 8.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 89.62% | 8.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.62% | 8.85% | |||
| EBIT | 89.05% | 18.25% | |||
| EBITDA | 89.07% | 18.25% | |||
| EPS Basic | 89.64% | 8.87% | |||
| Normalized Basic EPS | 89.60% | 8.87% | |||
| EPS Diluted | 89.64% | 8.87% | |||
| Normalized Diluted EPS | 89.60% | 8.87% | |||
| Average Basic Shares Outstanding | 0.23% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||